Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals, Inc. - Common Stock
(NQ:
ALNY
)
225.16
+1.34 (+0.60%)
Delayed Quote
Updated: 1:06 PM EDT, Oct 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
23
24
Next >
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
↗
January 18, 2023
Via
Benzinga
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
January 08, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease
↗
October 07, 2022
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
↗
October 03, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
3 Growth Stocks That Could Rocket Higher in 2023
↗
January 06, 2023
Upcoming binary events could push these stocks to new all-time highs.
Via
The Motley Fool
Alnylam Announces Updates to its Board of Directors
January 05, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
December 21, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Reinforces Patisiran Data In Stiff Heart Disorder Before Heading For FDA Approval
↗
October 03, 2022
Via
Benzinga
Meta To Rally Over 29%? Here Are 10 Other Price Target Changes For Friday
↗
December 16, 2022
Via
Benzinga
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
December 15, 2022
From
Alnylam Pharmaceuticals
Via
Business Wire
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
December 08, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Virtual R&D Day
December 08, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
↗
December 06, 2022
Via
Benzinga
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022
December 01, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
November 09, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Looking Into Alnylam Pharmaceuticals's Return On Capital Employed
↗
November 02, 2022
Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter.
Via
Benzinga
What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
↗
November 02, 2022
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Via
Benzinga
Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year
October 27, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program
↗
October 27, 2022
Via
Benzinga
Alnylam Pharmaceuticals: Q3 Earnings Insights
↗
October 27, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q3 earnings results on Thursday, October 27, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
October 27, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
↗
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
Where Alnylam Pharmaceuticals Stands With Analysts
↗
October 13, 2022
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Via
Benzinga
Roblox To $51? Plus Deutsche Bank Slashes PT On Deere & Company
↗
October 13, 2022
Via
Benzinga
Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results
October 13, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
3 Top Biotech Stocks Defying the Bear Market
↗
October 11, 2022
Bear market, shmear market. These biotech stocks are soaring despite the market downturn.
Via
The Motley Fool
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
October 06, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Where Alnylam Pharmaceuticals Stands With Analysts
↗
October 03, 2022
Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
What 12 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
↗
October 03, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
23
24
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
